194 related articles for article (PubMed ID: 22048717)
1. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo.
Lin J; Huo R; Wang L; Zhou Z; Sun Y; Shen B; Wang R; Li N
Cancer Immunol Immunother; 2012 May; 61(5):677-87. PubMed ID: 22048717
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone Inhibits TGF-β1-Induced Cell Migration by Regulating the ERK and AKT Pathways in Human Colon Cancer Cells Via CYR61.
Han S; Bui NT; Ho MT; Kim YM; Cho M; Shin DB
Cancer Res Treat; 2016 Jul; 48(3):1141-53. PubMed ID: 26693911
[TBL] [Abstract][Full Text] [Related]
3. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.
Gründker C; Bauerschmitz G; Schubert A; Emons G
Int J Oncol; 2016 Jun; 48(6):2713-21. PubMed ID: 27098123
[TBL] [Abstract][Full Text] [Related]
4. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
5. Baicalein Inhibits Epithelial to Mesenchymal Transition via Downregulation of Cyr61 and LOXL-2 in MDA-MB231 Breast Cancer Cells.
Nguyen LT; Song YW; Cho SK
Mol Cells; 2016 Dec; 39(12):909-914. PubMed ID: 28008161
[TBL] [Abstract][Full Text] [Related]
6. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis.
Huang YT; Lan Q; Lorusso G; Duffey N; Rüegg C
Oncotarget; 2017 Feb; 8(6):9200-9215. PubMed ID: 27911269
[TBL] [Abstract][Full Text] [Related]
7. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-CCN1 monoclonal antibody suppresses Rac-dependent cytoskeletal reorganization and migratory activities in breast cancer cells.
Jim Leu SJ; Sung JS; Huang ML; Chen MY; Tsai TW
Biochem Biophys Res Commun; 2013 May; 434(4):885-91. PubMed ID: 23618859
[TBL] [Abstract][Full Text] [Related]
9. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
Fromigue O; Hamidouche Z; Vaudin P; Lecanda F; Patino A; Barbry P; Mari B; Marie PJ
J Bone Miner Res; 2011 Jul; 26(7):1533-42. PubMed ID: 21312266
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for the recognition of CCN1 by monoclonal antibody 093G9.
Zhong C; Huo R; Hu K; Shen J; Li D; Li N; Ding J
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608634
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.
Sarkissyan S; Sarkissyan M; Wu Y; Cardenas J; Koeffler HP; Vadgama JV
PLoS One; 2014; 9(7):e103534. PubMed ID: 25062088
[TBL] [Abstract][Full Text] [Related]
12. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Zhang F; Chen H; Du J; Wang B; Yang L
Med Sci Monit; 2018 Sep; 24():6093-6101. PubMed ID: 30171812
[TBL] [Abstract][Full Text] [Related]
14. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer.
Vellon L; Menendez JA; Lupu R
Oncogene; 2005 May; 24(23):3759-73. PubMed ID: 15782133
[TBL] [Abstract][Full Text] [Related]
15. Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo.
Du J; Wang XF; Zhou QM; Zhang TL; Lu YY; Zhang H; Su SB
Oncol Rep; 2013 Aug; 30(2):685-94. PubMed ID: 23708383
[TBL] [Abstract][Full Text] [Related]
16. CYR61 suppresses growth of human malignant melanoma.
Chen J; Liu Y; Sun Q; Wang B; Li N; Chen X
Oncol Rep; 2016 Nov; 36(5):2697-2704. PubMed ID: 27665942
[TBL] [Abstract][Full Text] [Related]
17. Cyr61 as mediator of Src signaling in triple negative breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Mayoral-Varo V; Molinari A; Wagner KU; Losada JP; Ciordia S; Albar JP; Martín-Pérez J
Oncotarget; 2015 May; 6(15):13520-38. PubMed ID: 25980494
[TBL] [Abstract][Full Text] [Related]
18. Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells.
Chin LH; Hsu SP; Zhong WB; Liang YC
Mol Carcinog; 2016 May; 55(5):622-32. PubMed ID: 25773758
[TBL] [Abstract][Full Text] [Related]
19. Pro-metastatic functions of Notch signaling is mediated by CYR61 in breast cells.
Ilhan M; Kucukkose C; Efe E; Gunyuz ZE; Firatligil B; Dogan H; Ozuysal M; Yalcin-Ozuysal O
Eur J Cell Biol; 2020 Apr; 99(2-3):151070. PubMed ID: 32005345
[TBL] [Abstract][Full Text] [Related]
20. The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
Maity G; Haque I; Ghosh A; Dhar G; Gupta V; Sarkar S; Azeem I; McGregor D; Choudhary A; Campbell DR; Kambhampati S; Banerjee SK; Banerjee S
J Biol Chem; 2018 Mar; 293(12):4334-4349. PubMed ID: 29414775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
